Mérieux NutriSciences to acquire Provident Clinical Research & Consulting
The acquisition of Provident will allow the French company to offer global dedicated clinical research services in North America for the first time, and represents a “perfect complement” to the company’s existing nutrition business unit, Biofortis, said Philippe Sans, president and CEO of Mérieux NutriSciences Corporation.
“The addition of Provident to Biofortis will expand our ability to undertake high quality clinical trials to demonstrate the efficacy and safety of food, pharmaceutical and consumer health products,” said Dr Michel du Peloux Mérieux NutriSciences Sr VP and head of Biofortis.
“By combining Provident’s expertise and track record in metabolic and cardiovascular studies with Biofortis’ scale and its unique portfolio of scientific and research capabilities, we have strengthened our ability to deliver significant value,” added du Peloux.
